Fecal biomarkers of environmental enteric dysfunction and the gut microbiota of rural Malawian children: An observational study by Chaima, David et al.
Heliyon 7 (2021) e08194Contents lists available at ScienceDirect
Heliyon
journal homepage: www.cell.com/heliyonResearch articleFecal biomarkers of environmental enteric dysfunction and the gut
microbiota of rural Malawian children: An observational study
David Chaima a,b, Harry Pickering a, John D. Hart a, Sarah E. Burr a,b, Kenneth M. Maleta c,
Khumbo Kalua d,e, Robin L. Bailey a, Martin J. Holland a,*
a Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
b Department of Pathology, Microbiology Unit, College of Medicine, University of Malawi, Blantyre, Malawi
c School of Public Health and Family Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
d Blantyre Institute of Community Outreach, Blantyre, Malawi
e Department of Ophthalmology, College of Medicine, University of Malawi, Blantyre, MalawiH I G H L I G H T S Fecal concentrations of myeloperoxidase, alpha-1 antitrypsin and neopterin decreased with age in Malawian children.
 A marginal negative association was found between alpha diversity of the gut microbiota and fecal neopterin concentration.
 Succinivibrio abundance was higher in children with reduced composite environmental enteric dysfunction biomarker score.





Environmental enteric dysfunction* Corresponding author.
E-mail address: Martin.Holland@lshtm.ac.uk (M
https://doi.org/10.1016/j.heliyon.2021.e08194
Received 25 January 2021; Received in revised for
2405-8440/© 2021 The Author(s). Published by ElsA B S T R A C T
Environmental enteric dysfunction (EED) is a subclinical condition of the gut characterized by changes in
morphology and function with underlying chronic inflammatory responses. This study characterized composition
and diversity of the gut microbiota in rural Malawian children with and without signs of EED. Fecal samples were
collected from children aged 1–59 months. Neopterin, myeloperoxidase and alpha-1 antitrypsin concentrations
were quantified by ELISA and combined to form a composite EED score using principal component analysis. DNA
was extracted from fecal samples and V4-16S rRNA gene sequencing was used to characterize the gut microbiota.
The concentrations of all three biomarkers decreased with increasing age, which is consistent with other studies of
children living in similar low-income settings. Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria were the
dominant phyla while Faecalibacterium and Bifidobacterium were the most prevalent genera. Increased alpha di-
versity was associated with a reduction in neopterin concentration. Microbiota composition was different between
fecal samples with low and high composite EED scores; increased abundance of Succinivibrio was associated with
reduced composite EED scores.1. Introduction
The gut microbiota is essential in maintaining normal physiological
and metabolic processes. Changes in the gut microbiota composition and
function have been associated with a number of conditions including
environmental enteric dysfunction (EED) [1, 2]. EED is characterized by
partial villous atrophy, impaired enterocyte tight junctions and under-
lying chronic inflammatory responses. The specific cause of EED has not
been clearly established, however, one model suggests that ingestion of.J. Holland).
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evier Ltd. This is an open accesscontaminated food or water,changes the composition and function of the
gut microbiota, resulting in intestinal inflammation and morphological
changes to the intestinal epithelium thereby affecting normal gut func-
tion [2, 3]. EED affects more than two-thirds of children aged between
0-5 years living in low-income settings [4, 5] and has been linked with
growth faltering and reduced efficacy of oral vaccines [6].
Confirmation of a diagnosis of EED requires visualization of the in-
testinal epithelium using endoscopy or biopsy, however, these are
invasive tests that would be unethical to perform in asymptomaticOctober 2021
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extensively used in the past as a non-invasive test to diagnose EED,
however, the test is inconsistent; procedural details, including fasting
prior to ingestion, sugar dosage, time of urine collection and method of
detection, vary between studies making comparison of results difficult.
Leakage of urine sample from pediatric urine bags and urine contami-
nation by stool are other additional challenges in infants. Potential bio-
markers that can easily be quantified in fecal samples and blood using
ELISA techniques have been tested as biomarkers of EED [7, 8, 9, 10, 11].
These biomarkers are thought to measure the various processes involved
in EED, such as intestinal epithelial damage, intestinal inflammation,
intestinal permeability, microbial translocation and systemic inflamma-
tion [2]. Myeloperoxidase (MPO), alpha-1 antitrypsin (AAT) and neo-
pterin (NEO) are three potential biomarkers that have been evaluated for
use in EED diagnosis, although available data suggests that no single
biomarker is sufficient to indicate EED [6, 12]. Accordingly, a multi-site,
longitudinal study by Kosek et al. [13] combined the absolute measured
concentrations of AAT, MPO and NEO into a single metric, using prin-
cipal component analysis, to form a composite EED score. They then
explored the relationship between the composite EED score and linear
growth in infants from resource limited settings. That study reported an
association between higher composite EED scores and growth faltering.
In the present study, we used fecal samples collected from rural Mala-
wian children to characterize the fecal microbiota defined by V4 16S
rRNA gene sequencing and explored associations with EED indicated by
fecal levels of MPO, AAT and NEO.
2. Methods
2.1. Study design
This study utilized baseline samples from a nested cohort study,
conducted within the framework of a randomized controlled trial
(NCT02047981). The study design and methodology for sample selection
of both the nested cohort and the parent trial have been previously
described [14, 15, 16]. Within the nested cohort study, 102 baseline
samples from children residing in 30 clusters within the Mangochi dis-
trict were analysed by 16S rRNA gene sequencing. All sampled children
were aged between 1 and 59 months and weighed at least 3.8kg. Sample
collection took place between May and July 2015.
2.2. Fecal sample collection
Fecal samples for participating children were collected by their
mothers or guardians, who were provided with sterile fecal collection
bottles (Wheaton, UK) and given verbal instruction, by a nurse, on how to
collect the sample. Fecal samples were returned to the field team as soon
as possible after collection. These samples were put in a cool box with ice
packs until the end of the day (not more than 8 h after collection) and
were then brought to the laboratory where they were placed at -80 C for
storage.
2.3. Fecal biomarkers of EED
Commercially available ELISA kits for MPO (Immundiagnostik, Ger-
many), AAT (Immundiagnostik) and NEO (Genway, CA, USA) were used
for the quantification of each biomarker. Each assay was performed ac-
cording to the kit instructions using stool diluted 1/500 for MPO, 1/
25,000 for AAT and 1/100 in phosphate buffered saline (PBS) for NEO
[12]. Fecal samples with out-of-range concentration values were
re-tested at appropriate dilutions until in-range values were obtained.
2.4. 16S rRNA gene sequencing and sequence processing
16S rRNA gene sequencing and sequence processing were performed
as detailed elsewhere [15]. Briefly, DNA libraries were prepared by2
amplifying a ~390-bp V4 region of the 16S rRNA gene in genomic DNA
extracted from 250mg of fecal sample. The amplicons were purified and
then quantified on a Qubit 2.0 Fluorometer (Invitrogen) with
high-sensitivity reagents (Life Technologies) and thereafter pooled in
equimolar amounts. A PhiX-spiked DNA library was then assayed by 2 
300bp paired-end sequencing on the Illumina MiSeq platform for a total
of 600 cycles using a standard protocol [17].
Raw sequence data was processed in QIIME 2 [18] as per standard
practice [17] and de novo-clustered into operational taxonomic units
(OTUs) at  97% identity. Taxonomy was assigned to the OTUs using a
naïve Bayes classifier pre-trained on the SILVA 16S database [19] sub-
sequently generating an OTU table. To exclude spurious OTUs, only
bacterial OTUs identified to the genus level, with sequences more than
0.005% of the total number of sequences [20] and a frequency of more
than 0.01% in any sample were retained in the analyses.
2.5. Statistical analysis
Shannon (H) and Simpson (D) diversity indices were calculated from
the OTUs to indicate alpha diversity using the phyloseq R package [21].
The Shannon diversity index accounts for species richness and evenness
in a sample whereas the Simpson diversity index accounts for a propor-
tion of species in a sample. Larger Shannon and Simpson index scores
indicate higher diversity. The differences in Shannon and Simpson dis-
tribution between groups were statistically tested using ANOVA and the
non-parametric Kruskal-Wallis test respectively. Weighted and un-
weighted UniFrac distance matrices were also calculated to determine
bacterial phylogenetic distance between samples.
Median and interquartile range (IQR) concentration of individual
fecal biomarkers of EED were used to determine their distribution.
Published cut-off values for each of the 3 biomarkers [12, 13] were used
to determine proportions of fecal samples with elevated biomarkers.
Concentrations of the 3 biomarkers were combined to form a composite
EED score following the method of Kosek et al. [13] with the following
modification: absolute weightings instead of rounded weightings from
the principal component analysis [13] were used to generate continuous
EED scores.
Associations between alpha diversity indices and biomarker concen-
trations were investigated using regression analyses adjusted for age and
sex. PERMANOVA with 1000 permutation tests was run on weighted and
unweighted UniFrac distances to compare bacteria community compo-
sitional differences between groups; differences in UniFrac clustering by
groups were visualized using principal coordinate analysis (PCoA) plots.
Differential abundance analysis at the genus level was performed to
identify OTUs differentially abundant in EED using the DESeq2 package
in R [22]. Statistical significance of log2 fold changes was assessed using
the default Wald test with Benjamin-Hochberg p value correction. Cut-off
for all significant tests was set at p < 0.01. Zero-inflated negative bino-
mial regression analysis was conducted, adjusting for age and sex, to
establish the relationship between the differentially abundant OTUs and
the composite EED score.
PICRUSt2 [23] analysis was used to predict metagenomes from 16S
data and a reference genome database. We included OTU abundance data
from 102 baseline samples that passed previously described quality
control measures. Briefly, unique sequences representing the previously
defined OTUs were added to reference multiple-sequence alignments and
phylogeny containing 20000 full 16S rRNA genes of archaea and bacteria
from the Integrated Microbial Genome database [24]. Hidden-state
prediction based on position of OTU sequences in the reference phylog-
eny was used to predict gene family abundances. To estimate functional
profiles of each sample, gene family abundances per OTU were adjusted
for OTU abundance values per sample. Sample functional profiles were
finally utilized to infer MetaCyc pathway abundances. PICRUSt2 identi-
fied 431 metabolic pathways; these were collapsed to 67 superpathways
for downstream analysis. To explore associations between metabolic
pathways identified by PICRUSt2 and EED, only the 60 samples that had
Table 1. Age and sex distribution of all children involved in 16S sequencing and those who had sufficient sample available for MPO, AAT and NEO assays.
Variable All children (n ¼ 102) All three biomarkers (n ¼ 60) MPO (n ¼ 75) AAT (n ¼ 69) NEO (n ¼ 64)
Mean (SD) age in months 23.0 (13.5) 24.3 (13.8) 23.3 (13.8) 23.6 (14.1) 24.0 (13.7)
Male sex, n (%) 52 (51) 34 (57) 41 (55) 38 (55) 35 (55)
Figure 1. Distribution of individual biomarker concentrations and the composite EED score. (A) NEO, (B) AAT, (C) MPO and (D) composite EED score. Normal values
for the individual biomarkers were based on values reported in the literature (NEO 70 nmol/L, AAT 0.27 mg/g and MPO 2000 ng/ml) [6, 12, 13].
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calculate the composite EED score were included. In this subset of 60
samples, 15 super pathways had zero count score contribution and were
excluded from further analysis. Lasso regression was then used to identify
the inferred metabolic or functional properties of 16S rRNA community
that are important for EED, the tuning parameter (lambda) was chosen by
ten-fold cross-validation. Age-adjusted logistic regression analysis with
permuted p values was used to explore associations between pathways
predicted by PICRUSt2, and identified as important by the lasso regres-
sion model, and the composite EED score.2.6. Ethical considerations
This study was conducted in accordance with the Declaration of
Helsinki. It was approved by the London School of Hygiene and Tropical
Medicine Ethics Committee (UK) and the College of Medicine Research
Ethics Committee (Malawi). Information and consent forms were trans-
lated into local languages (Yao and Chichewa) prior to their approval by
the local ethics committee. Consent was first obtained at the communityTable 2. Median biomarker concentration by age.
*Biomarker concentration Age (months)
0–12 13–24
NEO (nmol/L) 2100 (2290), n ¼ 18 236 (402), n ¼ 18
AAT (mg/g) 0.16 (0.21), n ¼ 21 0.08 (0.09), n ¼ 18
MPO (ng/ml) 3591 (15998), n ¼ 22 1313 (2852), n ¼ 21
* Biomarker concentrations are presented as median (IQR).
a p value obtained from a Kruskal-Wallis test.
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level through discussions with the village chief and community elders
who then indicated the willingness, or unwillingness, of the community
to participate through verbal consent. Written, informed consent (by
thumbprint or signature) was then obtained from the parent or legal
guardian of each child for inclusion before they participated in the study.
During the consenting process, all parents and guardians were informed
of their freedom to withdraw their child from the study at any time
without giving reason for doing so.
3. Results
3.1. Distribution of individual biomarker concentration and the composite
EED score
One hundred and two baseline samples were analyzed by 16S rRNA
gene sequencing as detailed elsewhere [15]. Of these, 75 had sufficient
sample remaining to quantify MPO, 69 for AAT and 64 for NEO. A total of
60 fecal samples had ELISA results for all 3 biomarkers. The age and sex
of all 102 children who provided fecal samples for sequencing were not25–36 37–48 ap value
155 (340), n ¼ 12 187 (175), n ¼ 16 0.0003
0.06 (0.07), n ¼ 14 0.09 (0.14), n ¼ 16 0.006
1114 (1248), n ¼ 15 581 (979), n ¼ 17 0.0009
Figure 2. Comparison of the distribution of (A) Shannon and (B) Simpson indices by age group. p value for Shannon index (p < 0.001) was obtained from ANOVA
while p value for Simpson index (p ¼ 0.004) was obtained from the Kruskal-Wallis test.
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to quantify all the 3 biomarkers or any of the 3 biomarkers (Table 1).
The distribution of fecal biomarker concentrations was calculated in
all available samples and compared by age. The concentration of all three
biomarkers was skewed (Figure 1). A large proportion of children (81%)
had elevated NEO levels relative to reference values (Figure 1A). Ten
percent of the children had elevated levels of fecal AAT (Figure 1B) and
39% (29/75) of children had elevated MPO levels (Figure 1C). The 3
biomarkers were combined to form a composite EED score as described
and the range was plotted (Figure 1D). EED scores ranged from 0 (lowest
score) to 3.46 (highest score) with a median (IQR) of 2.26 (0.61).3.2. Effect of age on biomarker concentration
Age in months was categorized into 4 groups as follows: 0–12, 13–24,
25–36, and 37–60 and the Kruskal-Wallis test was used to test for the
differences in biomarker concentration among the groups. Median fecal
concentration for all the 3 biomarkers decreased with age (Table 2).Figure 3. Overall microbiota composition differences by age. (A) PCoA plot of un
weighted UniFrac distances (R2 ¼ 0.29, F ¼ 12.8, p ¼ 0.001). Children aged 0–12 m
were clustered in the positive space of PCo1. Children aged 13–24 months clustered
4
3.3. Gut microbiota and the effect of age
Characterization of the microbiota of this sample set has recently
been described [15]. Briefly, the 102 samples generated a total of 1,685,
792 reads with an average read depth per sample of 16,527  11,071.
Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria were the
dominant phyla while Faecalibacterium, Streptococcus, Bacteroides, Hae-
mophilus, Subdoligranulum, Bifidobacterium and Escherichia-Shigella were
the dominant genera. The mean (SD) Shannon index was 1.72 (0.45) and
median (IQR) Simpson index was 0.75 (0.16).
In the present study, the effect of age on Shannon or Simpson di-
versity indices and the composition of the microbiota was explored
among the 4 age groups. Shannon and Simpson indices were significantly
lower in fecal samples from younger children compared to older children,
indicating increasing diversity with age (Figure 2A, ANOVA p < 0.001
and Figure 2B, Kruskal-Wallis p ¼ 0.004 respectively).
Microbiota composition by age group was also examined using
PERMANOVA. Comparisons of weighted and unweighted UniFrac dis-
tance showed significant differences in clustering of microbialweighted UniFrac distances (R2 ¼ 0.17, F ¼ 6.4, p ¼ 0.001) (B) PCoA plot of
onths were clustered in the negative space of PCo1. Children aged >24 months
between 0-12 and 37–60 age groups.
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12.8, p ¼ 0.001 respectively) (Figure 3). Additionally, a comparison of
relative abundance of microbial taxa by age showed that fecal samples
from younger children (0–12 months) had a higher abundance of Acti-
nobacteria and a lower abundance of Bacteroidetes than samples from
older children (Kruskal-Wallis test p ¼ 0.01, Figure 4A). At the genus
level, a higher abundance of Bifidobacterium and a lower abundance of
genus Faecalibacteriumwere observed in younger children (0–12 months)
compared to the older age groups (Kruskal-Wallis test p ¼ 0.01,
Figure 4B).
3.4. Associations between alpha diversity and fecal biomarkers of EED
Linear regression analysis adjusted for age and sex was used to
examine the relationship between Shannon or Simpson diversity and
fecal concentrations of NEO, AAT and MPO. There was no relationship
between Shannon diversity and AAT or MPO concentrations, or between
Simpson diversity and AAT or MPO concentrations (Table 3). However,
there were marginal negative associations between both Shannon and
Simpson diversity, and NEO concentrations; increased Shannon or
Simpson diversity was associated with a decrease in NEO concentration
(Table 3). There was no association between Shannon or Simpson di-
versities and the composite EED scores (p ¼ 0.14 and P ¼ 0.33
respectively).
3.5. Associations between fecal bacterial community structure and
biomarkers of EED
PERMANOVA did not detect any differences in bacterial community
composition between normal and elevated biomarker concentration for
each of the 3 biomarkers (Table 4). However, PERMANOVA detected
significant differences in bacterial community composition between fecal
samples with low and high composite EED scores using unweighted (R2¼
0.04, F ¼ 2.53, p ¼ 0.011) and weighted UniFrac (R2 ¼ 0.05, F ¼ 3.35, p
¼ 0.017) (Figures 5A and B).
Differential abundance analysis at the genus level, both unadjusted
and adjusted for multiple comparison using Benjamin-Hochberg p value
correction, was performed to identify genera differentially abundantFigure 4. Relative abundance of taxa by age. (A) Relative abundance of phyla (B) R
genera; the remaining genera were grouped as “Other”.
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between low and high EED scores. Three genera, Succinivibrio, Butyrivi-
brio and Enterococcus, were differentially abundant in fecal samples with
high composite EED score compared to fecal samples with low composite
EED score (Table 5). An age and sex-adjusted zero-inflated negative
binomial regression model was used to further explore this relationship.
In the adjusted analysis, only Succinivibriowas associated with composite
EED score. An increase in the abundance of Succinivibrio was associated
with 0.14 reduced odds of a having a high composite EED score (Table 5).
3.6. Associations between predicted functional metagenome of the
microbiota and the composite EED score
We then used PICRUSt2 [23] analysis to predict metagenomes from
the 16S sequence data of all 102 baseline fecal samples. This method uses
evolutionary modelling to predict which gene families are present and
then combines gene families to estimate the composite metagenome and
their metabolic pathways. PICRUSt2 analysis predicted that the meta-
genome of these 102 fecal samples accounted for 431 metabolic path-
ways, which were collapsed to 67 superpathways for downstream
analysis (Supplementary table S1). To explore associations between
metabolic pathways identified by PICRUSt2 and the composite EED
score, we used the subset of 60 samples that had ELISA results for all the
three biomarkers. This sub-set of 60 samples was predicated to contain
52 of the 67 superpathways identified in the 102 sequenced samples, the
remaining 15 superpathways were excluded from further analysis. We
then used a lasso regression model to determine which of these metabolic
pathways weremost important for predicting the composite EED score, in
which the model coefficient for uninformative variables is reduced to
zero. Of the 52 pathways included in the final analysis, the lasso
regression model retained five pathways with non-zero coefficients
(Table 6). We then explored the relationship between these five path-
ways, and the composite EED score using age-adjusted logistic regression
analysis. Three of the five pathways were significantly associated with
reduced risk of high EED scores. A unit increase in the abundance of both
the fatty acid biosynthesis and pyrimidine nucleotide degradation path-
ways was associated with 0.47 reduced odds of high composite EED score
while a unit increase in the abundance of tetrapyrrole biosynthesis
pathway was associated 0.52 reduced odds of high composite EED score.elative abundance of genera. The stacked bar plot shows the 10 most abundant
Table 3. Relationship between alpha diversity indices and individual biomarkers of EED.
Variable AAT MPO NEO
Coefficient (95% CI) p value Coefficient (95% CI) p value Coefficient (95% CI) p value
Shannon index -0.15 (-0.34,0.05) 0.14 -1187 (-4377,2001) 0.46 -758.87 (-1496,-21) 0.04
Simpson index -0.61 (-1.31,0.09) 0.09 -607 (-11935,10721) 0.92 -2710 (-5386,-34) 0.047
CI ¼ confidence interval.
Coefficients (95%CI) and p values were obtained from linear regression models that were adjusted for age and sex.
Table 4. Association between bacterial community composition and individual
biomarkers of EED.
Variable Unweighted UniFrac Weighted UniFrac
R2 p value R2 p value
MPO 0.02 0.07 0.01 0.6
AAT 0.02 0.18 0.03 0.07
NEO 0.02 0.21 0.02 0.39
The R2 and p values were obtained with PERMANOVA using unweighted and
weighted UniFrac.
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degradation pathways and the composite EED score in this adjusted
analysis (Table 6).
4. Discussion
We estimated the magnitude of intestinal inflammation and permeability
in rural Malawian children using fecal biomarkers and explored associations
with the fecal microbiota, characterized by 16S rRNA gene sequencing. Our
study is one of the few studies that has explored the relationship between the
gut microbiota and EED using fecal biomarkers. We also inferred metabolic
pathways important in EEDusing PICRUSt2 analysis.We found elevated fecal
levelsofNEOinalmost two-thirdsof thechildren;MPOwasraised inone-third
of children whilst AAT was elevated in 10% of children. All biomarker levels
decreased with age, consistent with trends shown by previous studies from
similar low-income settings. In studies byNaylor et al. [6], Campbell et al. [25]
and McCormick et al. [12], more than 80% of infant fecal samples from low
incomesettingshadelevatedconcentrationsofMPO,AATandNEOrelative to
values from high income settings [6, 25] and all biomarker concentrations
decreased with age.
We also found an effect of age on the microbiota. Microbiota diversity
was higher in older age groups compared to younger children. Younger
children were shown to have a higher abundance of Actinobacteria and
Bifidobacterium, and a lower abundance of the Bacteroidetes andFigure 5. Overall microbiota composition differences by composite EED score. (A) PC
weighted UniFrac (R2 ¼ 0.05, F ¼ 3.35, p ¼ 0.017).
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Faecalibacterium compared to the older age groups. These findings are
consistent with trends reported by recent longitudinal studies [26, 27].
The increase in diversity and changes in intestinal microbiota seen with
the different age groups are also consistent with changes that have been
reported during the transition from breast-feeding to weaning [28, 29].
We did not find a relationship between alpha diversity and fecal levels
of AAT or MPO, however a marginal negative association was seen be-
tween alpha diversity and NEO, a biomarker of intestinal inflammation.
To date, there is no other published data available supporting a rela-
tionship between fecal microbiota diversity and intestinal inflammation
in EED, however, a reduction in fecal microbiota diversity has been re-
ported previously in inflammatory bowel disease [30, 31, 32], which is
consistent with our findings. These results suggest a potential role of the
gut microbiota in modulating inflammatory responses, however, we
cannot confidently infer the direction of the causal relationship i.e. do
changes in gut microbiota diversity drive inflammation or vice-versa.
There is limited published data indicating associations between in-
testinal bacterial community structure and EED. Recently, Ordiz et al.
found differences in intestinal bacterial composition between children
with increased versus normal intestinal permeability as measured by the
L:M ratio test [33]; the genera Succinivibrio, Klebsiella, and Clostridium_XI
were less prevalent in children with increased intestinal permeability
compared to children with normal levels. Similarly, we found an asso-
ciation between higher abundance of Succinivibrio and low composite
EED score. Succinivibrio is a gram-negative anaerobic commensal of the
human colon that has been associated with fiber-degradation [34, 35].
The association between Succinivibrio abundance and the composite EED
score, which is consistent with the results of others [33], indicates a
potential role for Succinivibrio in gut function.
Using the 16SrRNA sequencing data generated, PICRUSt2 analysis
predicted 67 metabolic pathways of which 5 were identified by the lasso
regression model as important for predicting EED. Among the 5 pathways,
the fatty acid biosynthesis, pyrimidine nucleotide degradation and tetra-
pyrrole biosynthesis pathwayswere significantly associatedwithcomposite
EED score in an age-adjusted logistic regressionmodel, which, to an extent,
supports the prediction accuracy of the lasso regression model. Fatty acidoA plot of unweighted UniFrac (R2 ¼ 0.04, F ¼ 2.53, p ¼ 0.011) (B) PCoA plot of
Table 5. Differentially abundant genera in fecal samples with high versus low composite EED scores.
Genus log2Fold
Change
lfcSE p valuea padjb ORc (95%CI) p valuec
Succinivibrio -26.3 2.6 <0.001 <0.001 0.14 (0.08,0.23) <0.001
Butyrivibrio -25.6 2.9 <0.001 <0.001 3.52 (0.68,18.16) 0.791
Enterococcus 23.5 2.9 <0.001 <0.001 1.82 (0.25,1.2) 0.619
OR ¼ odds ratio.
CI ¼ confidence interval.
lfcSE ¼ log fold change Standard Error obtained with a differential abundance analysis.
a Denotes unadjusted p value obtained with differential abundance analysis while.
b denotes p value obtained with differential abundance analysis after adjusting for multiplicity with Benjamin-Hochberg p value correction.
c Denotes OR (95%CI) and p values obtained with zero-inflated negative binomial regression (conditional model) after adjusting for age and sex.
Table 6. Associations between metabolic pathways and composite EED score.
Metabolic pathway aVariable
importance score
OR (95% CI) bp value
Pyrimidine nucleotide degradation 7.80E-05 0.47 (0.23,0.81) 0.006
Fatty Acid biosynthesis 4.79E-07 0.47 (0.23,0.86) 0.015
Tetrapyrrole biosynthesis 2.36E-05 0.52 (0.27,0.87) 0.015
Coenzyme B 7.52E-05 0.99 (0.87,1.05) 0.556
Catechol degradation 2.43E-04 0.99 (0.81,1.25) 0.982
CI ¼ confidence interval, OR ¼ odds ratio.
a Pathways with non-zero coefficients retained by lasso regression.
b Permuted (10,000) p value from an age-adjusted logistic regression.
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to help maintain the intestinal mucus barrier by regulating mucin 2 in
murine models [36]. In the present study, we found that an increase in the
relative abundance of the fatty acid biosynthesis pathway was associated
with reduced chance of high composite EED scores. As such, we can
postulate that the fatty acid biosynthesis pathway plays a role in the
maintenance of gut integrity in humans. For their part, pyrimidines serve
important roles in humanmetabolism, such as ribonucleotide bases in RNA
(uracil and cytosine) and deoxyribonucleotide bases in DNA (cytosine and
thymine). Some bacterial species are known to catabolize pyrimidines via a
reductive pathway leading to the formation of β-amino acids [37, 38]. Di-
etary supplementation of α-amino acids has been shown to improve intes-
tinalmucosadevelopment inanimals [39],however, there is limiteddataon
the role of β-amino acids formed from the pyrimidine nucleotide degrada-
tion pathway in gut function. Thus, the role of the pyrimidine nucleotide
degradation pathway in gut function should be explored further. The
tetrapyrrole biosynthesis pathway includes pathways in porphyrin (heme)
and corrinoid (cobalamin) metabolism. Some porphyrins have been shown
to have anti-inflammatory properties through the inhibition of the activity
of Fyn, a non-receptor Src-family tyrosine kinase, triggering
anti-inflammatory events associated with down-regulation of T-cell recep-
tor signal transduction, leading to inhibition of tumor necrosis factor alpha
(TNF-α) production [40]. In the present study, enrichment of the tetrapyr-
role biosynthesis pathway was associated with a reduced chance of high
composite EED score, a result consistent with the anti-inflammatory prop-
erties of components of the tetrapyrrole pathway.
The present study also found a higher abundance of Succinivibrio in
children with low composite EED scores. This bacterium has been asso-
ciated with metabolism of nondigestible dietary carbohydrates in
humans and animals [34, 35]. Among the 67 metabolic pathways pre-
dicted by PICRUSt2 in the present study, there were pathways that are
involved in carbohydrate metabolism such as the sugar degradation
pathway, however these pathways were not identified as being important
in predicting EED using the lasso regression model. Further studies are
needed to explore the correlations between Succinivibrio abundance,
carbohydrate metabolism and gut function.
In conclusion, our data suggest that there is an association between
intestinal microbiota diversity and intestinal inflammation as measured7
by fecal NEO. The genus Succinivibrio, which was reported by Ordiz
et al. [33] to be reduced in EED, was also associated with low composite
EED scores in our study. This bacterium has been associated with
fiber-degradation [34] and has recently been shown to be more abun-
dant in children consuming a diet rich in fiber in low-income settings
[35]. Future studies should further investigate the role of this bacterium
and the predicted metabolic pathways important in EED. Additionally,
the association between low composite EED score and higher abun-
dance of Succinivibrio, which is consistent with recent findings that used
the L:M ratio test to indicate EED [33] underscores the potential of the
composite EED score. Nevertheless, the use of the composite EED score
has not been comprehensively validated; future studies should aim to
validate it against the “gold standard” L:M ratio.
5. Limitations of the study
One of the limitations of this study is the use of EED biomarker values
from high income countries to define cut-off limits for normal or elevated
biomarker concentration. This limitation is not unique to this study; the
lack of reference values for the biomarkers of EED in children living in
low income settings has been cited by others [6, 12]. There is therefore a
need for large-scale studies to define reference values of the biomarkers
of EED in children living in low income settings. A further limitation was
that this was an opportunistic study that used previously collected sam-
ples and therefore may not have had adequate statistical power to
identify significant associations. A population-based survey would likely
have been more robust.
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